Literature DB >> 32050950

A bioinformatics investigation into the pharmacological mechanisms of the effect of the Yinchenhao decoction on hepatitis C based on network pharmacology.

Jingyuan Zhang1, Xinkui Liu1, Jiarui Wu2, Wei Zhou1, Jinhui Tian3, Siyu Guo1, Shan Shan Jia1, Ziqi Meng1, Mengwei Ni1.   

Abstract

BACKGROUND: Globally, more than 170 million people are infected with hepatitis C virus, a major cause of cirrhosis and hepatocellular carcinoma. The Yinchenhao Decoction (YCHD) is a classic formula comprising three herbal medicines. This decoction have long been used in China for clinically treating acute and chronic infectious hepatitis and other liver and gallbladder damp heat-accumulation disorders.
METHODS: In this study, we identified 32 active ingredients and 200 hepatitis C proteins and established a compound-predicted target network and a hepatitis C protein-protein interaction network by using Cytoscape 3.6.1. Then, we systematically analyzed the potential targets of the YCHD for the treatment of hepatitis C. Finally, molecular docking was applied to verify the key targets. In addition, we analyzed the mechanism of action of the predicted targets by the Kyoto Encyclopedia of Genes and Genomes and gene ontology analyses.
RESULTS: This study adopted a network pharmacology approach, mainly comprising target prediction, network construction, module detection, functional enrichment analysis, and molecular docking to systematically investigate the mechanisms of action of the YCHD in hepatitis C. The targets of the YCHD in the treatment of hepatitis C mainly involved PIK3CG, CASP3, BCL2, CASP8, and MMP1. The module and pathway enrichment analyses showed that the YCHD had the potential to influence varieties of biological pathways, including the TNF signaling pathway, Ras signaling pathway, PI3K-Akt signaling pathway, FoxO signaling pathway, and pathways in cancer, that play an important role in the pathogenesis of hepatitis C.
CONCLUSION: The results of this study preliminarily verified the basic pharmacological effects and related mechanisms of the YCHD in the treatment of hepatitis C.

Entities:  

Keywords:  Bioinformatics; Hepatitis C; Network pharmacology; Yinchenhao decoction

Year:  2020        PMID: 32050950     DOI: 10.1186/s12906-020-2823-y

Source DB:  PubMed          Journal:  BMC Complement Med Ther        ISSN: 2662-7671


  5 in total

1.  Dissecting the mechanism of Yuzhi Zhixue granule on ovulatory dysfunctional uterine bleeding by network pharmacology and molecular docking.

Authors:  Jialin Li; Hua Luo; Xinkui Liu; Jingyuan Zhang; Wei Zhou; Siyu Guo; Xiuping Chen; Yingying Liu; Shanshan Jia; Haojia Wang; Bingbing Li; Guoliang Cheng; Jiarui Wu
Journal:  Chin Med       Date:  2020-10-23       Impact factor: 5.455

2.  A Network Pharmacology-Based Approach to Investigating the Mechanisms of Fushen Granule Effects on Intestinal Barrier Injury in Chronic Renal Failure.

Authors:  Miaoru Han; Hangxing Yu; Kang Yang; Panying Liu; Haifeng Yan; Zhihua Yang; Hongtao Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-03-05       Impact factor: 2.629

3.  Downregulation of CYP2E1 is associated with poor prognosis and tumor progression of gliomas.

Authors:  Liguo Ye; Yang Xu; Long Wang; Chunyu Zhang; Ping Hu; Shi'ao Tong; Zhennan Liu; Daofeng Tian
Journal:  Cancer Med       Date:  2021-10-06       Impact factor: 4.452

4.  Identification of Key Genes Associated With the Process of Hepatitis B Inflammation and Cancer Transformation by Integrated Bioinformatics Analysis.

Authors:  Jingyuan Zhang; Xinkui Liu; Wei Zhou; Shan Lu; Chao Wu; Zhishan Wu; Runping Liu; Xiaojiaoyang Li; Jiarui Wu; Yingying Liu; Siyu Guo; Shanshan Jia; Xiaomeng Zhang; Miaomiao Wang
Journal:  Front Genet       Date:  2021-09-01       Impact factor: 4.599

Review 5.  Pathogenesis of Liver Fibrosis and Its TCM Therapeutic Perspectives.

Authors:  Yang Nan; HongChan Su; XiaoMei Lian; Juan Wu; SuJie Liu; PingPing Chen; ShuMin Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-28       Impact factor: 2.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.